Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-Daily

Next Previous
X
Search
Trial Profile

A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once-Daily

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Islatravir (Primary) ; Ulonivirine (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms IMAGINE-DR; MK-8591-013
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 28 Jun 2024 Planned End Date changed from 30 Sep 2024 to 18 Dec 2024.
    • 28 Jun 2024 Planned primary completion date changed from 30 Sep 2024 to 18 Dec 2024.
    • 12 Dec 2023 Planned End Date changed from 26 Dec 2023 to 30 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top